Amirali H. Salmasi, MD, presented “Biomarkers for Bladder Cancer” during the 30th Annual Perspectives in Urology: Point-Counterpoint, on March 10, 2023, at Humphreys Half Moon Inn, San Diego, California.
How to cite: Salmasi, Amirali H. “Biomarkers for Bladder Cancer.” March 10, 2023. Accessed Dec 2024. https://grandroundsinurology.com/biomarkers-for-bladder-cancer/
Biomarkers for Bladder Cancer – Summary
Amirali H. Salmasi, MD, delivers a comprehensive presentation on the significance of biomarkers in detecting and monitoring bladder cancer. He reviews the various types and classifications of biomarkers, and their role in identifying the presence or confirmation of diseases and medical conditions, including bladder cancer.
Dr. Salmasi focuses on the concept of response biomarkers, shedding light on how changes in biomarker levels can indicate the efficacy of exposure or treatment. He delves into the specific mechanisms and capabilities of URO17 and ADXBLADDER tests, both of which exhibit promising sensitivity and specificity in detecting bladder cancer.
Concluding the presentation, Dr. Salmasi emphasizes the need for large-scale validation studies to confirm the role of these biomarkers. He mentions the potential role of circulating free DNA, the emerging significance of microRNA, extracellular vesicles, exosomes, and artificial intelligence in revolutionizing the field of biomarker research.
About the 30th Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.
ABOUT THE AUTHOR
Amirali Salmasi, MD, is a urologist with expertise in the management of genitourinary cancers in men and women, including bladder, prostate, kidney, ureteral, testicular, adrenal, and penile cancers. He provides a personalized, multidisciplinary approach to deliver the best possible treatment options (active surveillance, focal therapy, surgery, radiation, systemic treatments, or clinical trials) for his patients.
Dr. Salmasi performs advanced minimally invasive and complex open surgeries, such as robotic-assisted laparoscopic cystectomy, nerve-sparing prostatectomy, retro-peritoneal lymph node dissection, adrenalectomy, and partial nephrectomy.
He is also interested in translational research and clinical trials in urologic oncology, and his hope is to bridge the gap between the bench and clinical research. He has published over 50 articles in peer-reviewed journals.
Dr. Salmasi completed a urologic oncology fellowship at the University of California, Los Angeles, and a urology residency at Rutgers Robert Wood Johnson Medical School. As a first step towards a career in academic medicine and research, he also did a postdoctoral fellowship at Johns Hopkins School of Medicine. He earned his medical degree from Tehran University of Medical Sciences and holds a master's degree in clinical research (MSCR) from UCLA Clinical and Translational Science Institute.
He is a member of the American Urological Association, the Society for Urologic Oncology and the American Society of Clinical Oncology.
